Selskabets formål er at drive industrivirksomhed og handel.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 13.5 mia. | 2.5 mia. | 20.4 mia. | 5.3 mia. | 4104 | |
CVR: 56759514
Secondary names: LEO A/S, LEO INDUSTRIES A/S, LEO GROUP A/S
Previous names: LØVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB
3 properties
Upgrade to Pro to see addresses, building data and ownership details
Compared to 130 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Companies in the same industry and area
CVR 26411238
CVR 36423641
CVR 39038323
CVR 40868151
CVR 46003780
LEO PHARMA A/S has shown a remarkable turnaround in financial health, achieving a significant revenue increase from 9.96 billion DKK in 2021 to 13.50 billion DKK in 2025, alongside a return to profitability with a profit of 2.49 billion DKK in 2025. Despite facing substantial losses in previous years, the company's equity has also improved, rising to 5.26 billion DKK in 2025 from a low of 1.95 billion DKK in 2022. Key strengths include its robust revenue growth and recovery in profit margins, although concerns remain regarding its past losses and overall debt management. With over 1,000 employees, LEO PHARMA holds a significant position in the pharmaceutical manufacturing industry, indicating resilience and potential for future growth.
AI-generated summary
Thomas Christian Facius joined the board
Peter Helt Jacobsen Haahr joined the board
Henrik Bo Andersson joined the board
Kasper Fangel joined the board
Allan Carsten Dahl joined the board
Karen Louise Lauesen joined the board
Christina Dahl joined the board
Thomas Christian Vaarby joined the board
Rifat Ramicevic left the board
Jannie Kogsbøll left the board
companydata.dk